Drug rechanneling: A novel paradigm for cancer treatment
Cancer continues to be one of the leading contributors towards global disease burden.
According to NIH, cancer incidence rate per year will increase to 23.6 million by 2030. Even …
According to NIH, cancer incidence rate per year will increase to 23.6 million by 2030. Even …
Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment
The ubiquitin-proteasome system (UPS) plays a central role in the degradation of cellular
proteins. Targeting protein degradation has been validated as an effective strategy for …
proteins. Targeting protein degradation has been validated as an effective strategy for …
Drug repurposing opportunities in pancreatic ductal adenocarcinoma
R Rebelo, B Polónia, LL Santos, MH Vasconcelos… - Pharmaceuticals, 2021 - mdpi.com
Pancreatic ductal adenocarcinoma (PDAC) is considered one of the deadliest tumors
worldwide. The diagnosis is often possible only in the latter stages of the disease, with …
worldwide. The diagnosis is often possible only in the latter stages of the disease, with …
Drug repurposing, an attractive strategy in pancreatic cancer treatment: preclinical and clinical updates
L De Lellis, S Veschi, N Tinari, Z Mokini, S Carradori… - Cancers, 2021 - mdpi.com
Simple Summary The purpose of this review is to provide an update on some of the most
promising non-oncology drugs that are already approved and that could be useful also in …
promising non-oncology drugs that are already approved and that could be useful also in …
Phase 1 trial of nelfinavir added to standard cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer
AE Garcia‐Soto, ND McKenzie, ME Whicker… - Cancer, 2021 - Wiley Online Library
Background Nelfinavir (NFV), an HIV‐1 protease inhibitor, has been shown to sensitize
cancer cells to chemoradiation (CRT). The objectives of this phase 1 trial were to evaluate …
cancer cells to chemoradiation (CRT). The objectives of this phase 1 trial were to evaluate …
The association between protease inhibitors and anal cancer outcomes in veterans living with HIV treated with definitive chemoradiation: a retrospective study
AK Yoder, DS Lakomy, Y Dong, S Raychaudhury… - BMC cancer, 2021 - Springer
Background The incidence of anal squamous cell carcinoma has been increasing,
particularly in people living with HIV (PLWH). There is concern that radiosensitizing drugs …
particularly in people living with HIV (PLWH). There is concern that radiosensitizing drugs …
Elucidation of the molecular interactions that enable stable interaction between HIV protease inhibitor ritonavir and human DNA repair enzyme ALKBH2: a molecular …
The human DNA repair enzyme AlkB homologue-2 and 3 (ALKBH2 and ALKKBH3) repairs
methyl adducts from genomic DNA. Overexpression of ALKBH2 and ALKBH3 has been …
methyl adducts from genomic DNA. Overexpression of ALKBH2 and ALKBH3 has been …
[PDF][PDF] Das Ovarialkarzinom unter besonderer Berücksichtigung der Entwicklung des aktuellen Therapiestandards in der Primärtherapie und Entwicklung neuer …
A Burges - 2021 - edoc.ub.uni-muenchen.de
Das Ovarialkarzinom unter besonderer Berücksichtigung der Entwicklung des aktuellen
Therapiestandards in der Primärtherapie un Page 1 Aus der Klinik und Poliklinik für …
Therapiestandards in der Primärtherapie un Page 1 Aus der Klinik und Poliklinik für …